Bio-surgical medical device developer LifeBond has won the Frost & Sullivan 2016 New Product Innovation Award for its LifeSeal surgical sealant. The product is a sealant designed to minimise staple-line leakage in gastrointestinal procedures.
LifeBond
The award is presented to companies that have developed an innovative product that leverages leading-edge technology and greatly benefits the customer.
"Anastomotic leakage is a major cause of serious complications following bowel repair involving increased hospital readmission and mortality rates. LifeBond's LifeSeal is the only GI surgical sealant derived from naturally available components that has been clinically tested to be a safe and effective alternative to synthetic and fibrin-based sealants," said Frost & Sullivan industry analyst Arjunvasan Ambigapathy. "LifeBond's ability to deliver an exclusive product that has the potential to bring a solution to an unmet need is both clinically significant and relevant. With its strong overall performance, LifeBond has earned Frost & Sullivan's 2016 New Product Innovation Award."
"The recognition by Frost & Sullivan is the latest in a stream of recently achieved milestones, including US Food and Drug Administration Investigational Device Exemption approval to initiate a pivotal clinical study and receipt of CE marking in Europe earlier this year," said LifeBond chief executive officer Gideon Sturlesi. "All of the above strongly validate the novelty and importance of the product as well as its clinical advantage in the surgical sealant market. It is our intention to continue building on this strong momentum in terms of clinical development and commercialisation to the benefit of patients, surgeons, and hospitals alike."